Selenia® Dimensions® System Features EUR EN
Selenia® Dimensions® System Features EUR EN
Mammography System
Selenia Dimensions
9000 Package Features
Selenia® Dimensions® System
6000 Features
The 2D/3D™ system that redefines ergonomics, matched with the
perfect balance of enhanced work flow features, taking your
performance to the next level.
Included paddles: 4
Standard Compression Paddles
24 cm x 29 cm Screening Paddle
18 cm x 24 cm Screening Paddle
Standard Diagnostic Paddles
10 cm Contact Paddle; 10 cm Contact Magnification Paddle;
Integrated UPS
Dynamic Tube Head Motion Licenses (ready for tomo and Bx)
I-View™ software option for Contrast Enhanced 2D (CE2D) Imaging, provides functional
imaging information and highly detailed 2D images for enhanced precision in breast
cancer detection.
C-View™ software option generates 2D images from the tomo data set, reducing patient’s
radiation dose and time under compression.
* Superiority of 3D™ imaging versus stereo-tactic 2D biopsy procedures. For complete details, including standard and optional equipment, accessories and specifications, refer to the Selenia Dimensions system data sheet.
References:
1. Results from Friedewald, SM, et al. “Breast cancer screening using tomosynthesis in combination with digital mammography.” JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000
screening mammograms investigating the initial impact the introduction of the Hologic Selenia Dimensions on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95%
CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D
FFDM mammograms only. 2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. 3. Bernardi D, Macaskill P, Pellegrini
M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016
Aug;17(8):1105-13. 4. FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005. 5. Rafferty EA, Durand MA, Conant EF, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and
Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6. 6. Schrading S, Martine D, Dirrichs T, et al. “Digital Breast Tomosynthesis-guided Vacuum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone Stereotactic Vacuum-
assisted Biopsy.” Radiology. 2015 274:3, 654-662 E-pub 2014 Nov 12. 7. Schrading S, Martine D, Dirrichs T, et al. “Digital Breast Tomosynthesis-guided Vacuum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone
Stereotactic Vacuum-assisted Biopsy.” Radiology. 2015 274:3, 654-662 E-pub 2014 Nov 12.
MISC-03514-EUR-EN Rev.001 (7/17) ©2017 Hologic Inc. All rights reserved. Hologic, 3D, 3D Mammography, Affirm, C-View, Dimensions,, I-View, Selenia, and The Science of Sure are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where
such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products
are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.
No Compromise. No Comparison.